| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| EVOGENE Aktie jetzt für 0€ handeln | |||||
| 30.09. | Evogene Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.09. | Evogene Ltd. - 6-K, Report of foreign issuer | 10 | SEC Filings | ||
| 19.08. | Evogene Q2 2025: Kostensenkungen federn verfehlte Umsatz- und Gewinnziele ab | 3 | Investing.com Deutsch | ||
| 19.08. | Evogene GAAP EPS of -$0.85 misses by $0.22, revenue of $0.88M misses by $0.05M | 1 | Seeking Alpha | ||
| 19.08. | Evogene Reports Second Quarter 2025 Financial Results | 126 | PR Newswire | Conference call and webcast: today, August 19, 2025, 9:00 am ET
Financial Highlights:
The financial results for the first half of 2025 of Lavie Bio, a subsidiary... ► Artikel lesen | |
| 18.08. | Evogene Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 18.08. | Preview: Evogene's Earnings | 1 | Benzinga.com | ||
| 12.08. | Evogene startet KI-gestützte Forschungskooperation mit Universität Tel Aviv zur Behandlung von Stoffwechselerkrankungen | 2 | Investing.com Deutsch | ||
| 12.08. | Evogene partners with Tel Aviv University to develop metabolic disease treatments | 2 | Investing.com | ||
| 11.08. | Evogene Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.07. | Evogene Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 08.07. | Evogene Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.06. | Evogene Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 11.06. | Evogene, Google Cloud Launch AI Model For Breakthrough Small Molecule Discovery | 4 | RTTNews | ||
| 10.06. | Evogene Shares Surge On Completion Of Generative AI Foundation Model Developed With Google Cloud | 3 | RTTNews | ||
| 10.06. | Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud | 256 | PR Newswire | The new model addresses the challenge of identifying novel small molecules that meet multiple product criteria, an essential requirement for pharma and agriculture... ► Artikel lesen | |
| 05.06. | Evogene Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.05. | Evogene stock target cut to $3.50, maintains buy at Lake Street | 2 | Investing.com | ||
| 21.05. | Evogene GAAP EPS of -$0.38, revenue of $2.44M | 3 | Seeking Alpha | ||
| 21.05. | Evogene Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,70 | 0,00 % | BioNTech startet milliardenschweres Umtauschangebot für CureVac-Aktien | BioNTech hat das öffentliche Umtauschangebot für alle ausstehenden Aktien von CureVac N.V. gestartet. Das Angebot basiert auf dem Kaufvertrag vom 12. Juni 2025 und sieht vor, dass jede CureVac-Aktie... ► Artikel lesen | |
| QIAGEN | 41,000 | -0,34 % | QIAGEN N.V.: QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing | QIAcube Connect drives lab efficiency by automating critical steps in molecular biology workflows for both research and clinical customers Milestone builds on nearly 13,000 cumulative placements... ► Artikel lesen | |
| CUREVAC | 4,572 | -0,57 % | BionTech Aktie startet Übernahme von CureVac - Jetzt Aktien kaufen? | ||
| MODERNA | 21,950 | -2,42 % | Tesla- & IBM-Bilanzen enttäuschen - D-Wave, Moderna, Honeywell, T-Mobile US | Nach dem Rekordlauf vom Dienstag haben die Anleger an der Wall Street am Mittwoch Kasse gemacht. Der Dow Jones verlor zum Handelsschluss 0,71 Prozent. Besonders deutlich fiel die Korrektur im Technologiesektor... ► Artikel lesen | |
| STRYKER | 324,20 | +0,46 % | Dividendenbekanntmachungen (30.09.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIA REALTY TRUST US0042391096 0,2 USD 0,1705 EUR ADVANCED FLOWER CAPITAL INC US00109K1051 0,15 USD 0,1279 EUR AG MORTGAGE INVESTMENT... ► Artikel lesen | |
| BIOGEN | 128,00 | -0,27 % | Biogen Inc.: Health Canada Grants Authorization for "LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease | TOKYO and CAMBRIDGE, Mass., Oct. 26, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 56,00 | +0,90 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 564,00 | +0,82 % | Paradigmenwechsel in der Glaukommedizin? NurExone erzielt dosisabhängige Wiederherstellung des Sehvermögens | ||
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,180 | -1,80 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa., Oct. 2, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,534 | +4,36 % | Sangamo Therapeutics: Die Chance ist noch nicht vom Tisch! | ||
| INFLARX | 1,279 | -1,24 % | InflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company")... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 12,280 | +2,80 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) | CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| EDITAS MEDICINE | 2,659 | -1,48 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen |